The lawsuit claims the J&J subsidiary, Jassen Biotech, and its partner BTG , deceived the U.S. Patent and Trademark office when seeking a patent for its prostate cancer drug Zytiga. Prosecutors allege the drugmaker failed to disclose certain information to the trademark office and ultimately allowed the drugmaker to delay generic rivals’ entrance to the market.
“When big pharma engages in anti-competitive tactics to maintain its profits and harms the city, we will enforce the law to both recover damages and deter future fraudulent conduct. The city needs every dollar for essential services,” Baltimore City Solicitor Andre Davis told STAT.
Last month, Blue Cross Blue Shield of Louisiana filed a similar suit against Janssen, accusing it of filing “sham” patent litigation to keep generic forms of a different prostate cancer drug, Zytiga, off the shelves to maintain a monopoly.
Read more here.
More articles on pharmacy:
How hospitals can better align the pharmacy to achieve its strategic goals
Google sister-company Verily partners with big pharma for clinical trials
Merck’s Keytruda fails late-stage trial as standalone treatment for breast cancer
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
